Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

Shinohara, Nobuo; Obara, Wataru; Tatsugami, Katsunori; Naito, Sei; Kamba, Tomomi; Takahashi, Masayuki; Murai, Sachiyo; Abe, Takashige; Oba, Koji; Naito, Seiji

Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy

Shinohara, Nobuo; Obara, Wataru; Tatsugami, Katsunori et al.

Cancer science, 2015, 106(5), 618-626

Permalink : https://hdl.handle.net/2115/59497

このアイテムのアクセス数:1,283件（2026-10-08 23:46 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
cas12646	pdf	1.61 MB	1,181

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/59497
タイトル	Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
著者	Shinohara, Nobuo ; Obara, Wataru ; Tatsugami, Katsunori ; Naito, Sei ; Kamba, Tomomi ; Takahashi, Masayuki ; Murai, Sachiyo ; Abe, Takashige ; Oba, Koji ; Naito, Seiji
e-Rad_Researcher 90250422 著者名 Shinohara, Nobuo
e-Rad_Researcher 90337155 著者名 Obara, Wataru
e-Rad_Researcher 90380617 著者名 Tatsugami, Katsunori
著者名 Naito, Sei
e-Rad_Researcher 20402836 著者名 Kamba, Tomomi
e-Rad_Researcher 50325255 著者名 Takahashi, Masayuki
著者名 Murai, Sachiyo
e-Rad_Researcher 10399842 著者名 Abe, Takashige
e-Rad_Researcher 30422926 著者名 Oba, Koji
e-Rad_Researcher 40164107 著者名 Naito, Seiji
言語	英語
キーワード	Metastasis
	molecular-targeted therapy
	prognosis
	renal cell carcinoma
	risk classification
発行日	2015-05
出版者	Wiley-Blackwell
収録物名	Cancer science
巻(号)	106(5)
ページ	618-626
抄録	A multicenter cooperative study was conducted to clarify the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy and the clinical usefulness of the Japanese metastatic renal cancer (JMRC) prognostic classification. Of 389 consecutive patients for whom treatment was started between 2008 and 2010 at 23 hospitals in Japan, 357 patients who received vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) or cytokine as initial systemic therapy were the subject of the present study. Patients were classified into three prognostic groups according to the JMRC prognostic classification. The endpoints were progression-free survival (PFS) and overall survival (OS) after the start of the initial treatment. The median PFS and OS for the entire cohort of 357 patients were 9.1 and 27.2months, respectively. VEGFR-TKI were selected for patients with multiple organ metastases, those with liver metastasis, and those with bone metastasis. The median PFS and OS were 11.0 and 23.2months and 5.4 and 38.2months in the VEGFR-TKI group and the cytokines group, respectively. The JMRC prognostic classification was useful as a prognostic model for PFS and OS (c-indexes: 0.613 and 0.630 in patients who initially received VEGFR-TKI and 0.647 and 0.642 in patients who received cytokines, respectively). The present study showed for the first time the prognosis of Japanese patients with metastatic renal cell carcinoma in the era of molecular-targeted therapy. The JMRC prognostic classification may be clinically useful as a prognostic model.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN	1347-9032
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/cas.12646